研究单位：[1]Binhui Biopharmaceutical Co., Ltd.[2]Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology,Wuhan,Hubei,China,430000
This Ⅱ study evaluates the safety and efficacy of intratumoral injection of OH2 in locally advanced or metastatic bladder cancer. OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response.
